Study Phase 2

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Trial Information

Generic NameApalutamideProduct NameERLEADA®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassEndocrine TherapyPharmacological SubgroupHormone Antagonists and Related AgentsChemical SubgroupAnti-AndrogensCondition StudiedNeoplasms, Salivary Gland
Sponsor Protocol Number56021927SGT2001Enrollment31Data PartnerJohnson & Johnson% Female3.2%Mean/Median Age (Years)65.0% White0.0%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.